We are live on
!
Find out more
Rafferty Asset Management Portfolio holdings
AUM
$24.6B
1-Year Est. Return
47.06%
This Fund
S&P 500
This Quarter
Est. Return
+14.54%
1 Year Est. Return
+47.06%
3 Year Est. Return
+108.18%
5 Year Est. Return
+135.84%
10 Year Est. Return
+427.13%
AUM
$30.8B
AUM Growth
+$518M
(+1.7%)
Cap. Flow
-$2.73B
Cap. Flow
% of AUM
-8.84%
Top 10 Holdings %
Top 10 Hldgs %
39.95%
Holding
1,143
New
66
Increased
528
Reduced
508
Closed
39
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Astera Labs
ALAB
|
+$176M |
| 2 |
Credo Technology Group
CRDO
|
+$154M |
| 3 |
MACOM Technology Solutions
MTSI
|
+$71.5M |
| 4 |
Rambus
RMBS
|
+$69.5M |
| 5 |
NVMI
Nova
NVMI
|
+$68.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$386M |
| 2 |
NVIDIA
NVDA
|
+$300M |
| 3 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$272M |
| 4 |
Broadcom
AVGO
|
+$248M |
| 5 |
Qualcomm
QCOM
|
+$184M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 45.44% |
| 2 | Financials | 9.98% |
| 3 | Consumer Discretionary | 8.65% |
| 4 | Healthcare | 3.7% |
| 5 | Industrials | 2.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1076
Nice
NICE
$5.79B
| $201K | ﹤0.01% |
+1,390
| New | +$209K |
|
|
SF
1077
Stifel
SF
$12.6B
| $200K | ﹤0.01% |
+2,648
| New | +$198K |
|
1078
Ocular Therapeutix
OCUL
$1.79B
| $194K | ﹤0.01% |
16,571
+3,158
| +24% | +$37.8K |
|
1079
Innoviva
INVA
$1.55B
| $189K | ﹤0.01% |
+10,356
| New | +$202K |
|
1080
Core Scientific
CORZ
$6.66B
| $189K | ﹤0.01% |
+10,524
| New | +$154K |
|
1081
CorMedix
CRMD
$591M
| $174K | ﹤0.01% |
+14,987
| New | +$181K |
|
|
CNH
1082
CNH Industrial
CNH
$12.7B
| $166K | ﹤0.01% |
15,344
+80
| +0.5% | +$977 |
|
|
AVDL
1083
DELISTED
Avadel Pharmaceuticals
AVDL
| $164K | ﹤0.01% |
+10,726
| New | +$140K |
|
1084
Amneal Pharmaceuticals
AMRX
$5.85B
| $155K | ﹤0.01% |
15,443
-1,541
| -9% | -$13.8K |
|
1085
TeraWulf
WULF
$8.75B
| $152K | ﹤0.01% |
13,325
+1,293
| +11% | +$9.88K |
|
|
DFTX
1086
Definium Therapeutics
DFTX
$5.78B
| $149K | ﹤0.01% |
+12,675
| New | +$118K |
|
1087
Nuvation Bio
NUVB
$2.2B
| $148K | ﹤0.01% |
39,905
+11,539
| +41% | +$31.4K |
|
1088
Avantor
AVTR
$9.32B
| $147K | ﹤0.01% |
11,779
-114
| -1% | -$1.47K |
|
1089
Cipher Digital
CIFR
$9.13B
| $146K | ﹤0.01% |
11,618
+279
| +2% | +$2.1K |
|
1090
Xeris Biopharma Holdings
XERS
$1.39B
| $142K | ﹤0.01% |
17,411
-8,492
| -33% | -$56.4K |
|
1091
UiPath
PATH
$6.61B
| $135K | ﹤0.01% |
+10,057
| New | +$119K |
|
1092
Trevi Therapeutics
TRVI
$2.59B
| $124K | ﹤0.01% |
13,566
+2,583
| +24% | +$19.4K |
|
|
ATYR
1093
aTyr Pharma
ATYR
$47.6M
| $123K | ﹤0.01% |
+170,610
| New | +$773K |
|
1094
Wave Life Sciences
WVE
$1.09B
| $122K | ﹤0.01% |
16,621
+3,138
| +23% | +$25.4K |
|
1095
Arvinas
ARVN
$518M
| $115K | ﹤0.01% |
+13,494
| New | +$102K |
|
1096
Zevra Therapeutics
ZVRA
$562M
| $113K | ﹤0.01% |
+11,879
| New | +$119K |
|
|
WRD
1097
WeRide Inc
WRD
$1.91B
| $109K | ﹤0.01% |
10,986
-4,206
| -28% | -$39.9K |
|
1098
indie Semiconductor
INDI
$682M
| $108K | ﹤0.01% |
26,552
-34,379
| -56% | -$142K |
|
1099
Smith & Wesson
SWBI
$651M
| $106K | ﹤0.01% |
10,748
-655
| -6% | -$5.59K |
|
1100
Polestar Automotive Holding UK
PSNY
$2.09B
| $96.9K | ﹤0.01% |
3,436
-118
| -3% | -$3.78K |
|
Similar funds
CS
AF
SC
JG
Rafferty Asset Management's Q3 2025 Portfolio in Review
As of Q3 2025, Rafferty Asset Management held 1,143 positions worth $30.8B, up 1.7% from $30.3B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Rafferty Asset Management withdrew a net $2.73B in Q3 2025, closing 39 positions and reducing 508 holdings. Its most notable exit was Qorvo, an estimated $103M position sold in full.
By sector, the portfolio is most concentrated in Technology at 45% of assets, down from 49% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Rafferty Asset Management opened a new position in Astera Labs worth $210M.
- Rafferty Asset Management's largest Q3 2025 buy was Astera Labs: 1,070,475 shares worth $210M.
- Rafferty Asset Management added most to Invesco QQQ Trust in Q3 2025, an estimated $42.9M increase.
- Rafferty Asset Management's biggest Q3 2025 reduction was Advanced Micro Devices, cutting an estimated $386M.
- Rafferty Asset Management fully exited Qorvo in Q3 2025, selling an estimated $103M.
- Rafferty Asset Management's ten largest holdings make up 40% of its $30.8B portfolio in Q3 2025.
- Rafferty Asset Management opened 66 new positions and closed 39 in Q3 2025.
- Rafferty Asset Management's portfolio value rose 1.7% quarter-over-quarter to $30.8B.
Based on Rafferty Asset Management's 13F filing for Q3 2025, filed 12 Nov 2025.